Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Rhea-AI Summary
Palvella Therapeutics (Nasdaq: PVLA) reported new Phase 2 TOIVA data for topical QTORIN™ rapamycin in cutaneous venous malformations (VMs), presented at the 83rd Society for Investigative Dermatology meeting.
Among patients with baseline bleeding (n=4), cVM-IGA Bleeding improved by +2.5 points (p=0.003) and 100% were "satisfied" or "very satisfied" with treatment at Week 12. Baseline qualitative interviews highlighted substantial physical, functional, and psychosocial burden. Palvella notes QTORIN rapamycin could potentially become the first FDA-approved therapy for an estimated 75,000+ U.S. patients with cutaneous VMs.
Positive
- Bleeding patients mean cVM-IGA Bleeding improvement of +2.5 points at Week 12 (p=0.003)
- 100% of bleeding-baseline patients rated bleeding as Much or Very Much Improved at Week 12
- 100% of bleeding-baseline patients were satisfied or very satisfied with QTORIN rapamycin at Week 12
- Phase 2 TOIVA trial achieved statistical significance on multiple pre-specified efficacy endpoints
- QTORIN rapamycin described as potentially first FDA-approved therapy for ~75,000+ U.S. cutaneous VM patients
Negative
- None.
News Market Reaction – PVLA
In the May 15 session, PVLA declined 3.98%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Phase 2 trial start | Positive | +0.6% | First patients dosed in Phase 2 LOTU angiokeratomas trial of QTORIN gel. |
| Apr 20 | Conference presentations | Positive | -0.5% | Late-breaking presentations accepted for Phase 3 SELVA and Phase 2 TOIVA results. |
| Feb 24 | Phase 3 topline data | Positive | +37.1% | Positive topline Phase 3 SELVA results in microcystic lymphatic malformations. |
| Dec 16 | Fast Track designation | Positive | +8.8% | FDA Fast Track designation for QTORIN gel in angiokeratomas with planned Phase 2. |
| Dec 15 | Phase 2 topline data | Positive | -9.7% | Positive topline Phase 2 TOIVA results in cutaneous venous malformations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical trial news has often led to gains for PVLA, but there are several instances where shares declined despite favorable data.
Over the past six months, PVLA has repeatedly highlighted progress for QTORIN™ rapamycin across rare vascular and dermatologic conditions. Clinical milestones include positive Phase 3 SELVA topline data in microcystic lymphatic malformations on Feb 24, 2026 and multiple updates on Phase 2 programs such as TOIVA and LOTU. Reactions to these clinical announcements have been mixed: some events saw strong rallies, while others produced modest moves or pullbacks, underscoring variable market responses even to statistically significant results.
Key Terms
phase 2 medical
single-arm medical
open-label medical
patient-reported outcomes medical
patient-focused drug development framework regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Baseline qualitative patient interviews underscore the substantial physical, functional, and psychosocial burden of cutaneous venous malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 75,000 individuals with cutaneous venous malformations in the U.S.
WAYNE, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced new data from the Phase 2 TOIVA trial of QTORIN™ rapamycin in patients with cutaneous venous malformations (VMs) were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology (SID) in Chicago, IL. The poster presentation can be found here.
“Bleeding is a common and serious problem caused by cutaneous venous malformations. The TOIVA study showed that QTORIN™ rapamycin significantly reduced bleeding and improved the appearance and height of lesions in most patients,” said Dr. Michael Kelly, pediatric hematologist-oncologist at the Cleveland Clinic’s Vascular Anomalies Program and Executive Director of the Lymphangiomatosis & Gorham’s Disease Alliance (LGDA). “Cutaneous venous malformations affect many aspects of a patient’s life, resulting in pain, functional limitations, and mental health issues. TOIVA showed a strong correlation between improvements in clinical measures and patient-reported outcomes, suggesting that QTORIN™ rapamycin could potentially reduce the overall burden of this rare disease.”
TOIVA is a Phase 2, single-arm, open-label, baseline-controlled clinical trial of QTORIN™ rapamycin administered topically once daily for a 12-week efficacy evaluation period followed by a 12-week treatment extension period, for cutaneous VMs. As previously announced in December 2025, TOIVA achieved statistical significance on multiple pre-specified clinician-reported and patient-reported efficacy endpoints. New data presented at the 83rd Annual Meeting of the Society for Investigative Dermatology demonstrated statistically significant reduction in lesion bleeding in TOIVA and highlighted the multidimensional quality-of-life (QoL) burden for individuals living with cutaneous venous malformations as captured by baseline qualitative patient interviews.
cVM-IGA: Bleeding improvement in patients with bleeding at baseline
- Patients with bleeding at baseline (n=4) demonstrated a statistically significant improvement in change in cVM-IGA Bleeding scores at Week 12 with a mean effect size of +2.5 (p=0.003). cVM-IGA Bleeding is a 7-point clinician-assessed dynamic scale measuring change in bleeding from baseline to Week 12, ranging from “Very Much Worse” (-3) to “Very Much Improved” (+3).
- At week 12,
100% of patients (4/4) were either “Much Improved” (+2) or “Very Much Improved” (+3) on the cVM-IGA Bleeding at Week 12. 100% of patients with bleeding at baseline reported being "satisfied" or "very satisfied" with QTORIN™ rapamycin on the overall satisfaction item of the Treatment Satisfaction Questionnaire for Medication at Week 12.
Baseline qualitative patient interviews highlight multidimensional quality-of-life (QoL) burden of cutaneous VMs
- A pre-specified patient qualitative interview sub-study was incorporated to systematically capture the patient experience, including the symptoms, functional impacts, and treatment-related changes most meaningful to patients, consistent with FDA’s Patient-Focused Drug Development framework.
- QoL burden extends beyond clinical lesion severity, including bluish discoloration, pain/discomfort, swelling, protrusions, and bleeding or leakage.
- Patients reported limitations in physical activity, social participation, and work/school functioning, as well as emotional distress related to lesion visibility.
- Treatment priorities included improving appearance, reducing pain, and decreasing lesion size, highlighting patient-important domains not fully captured by traditional clinical severity assessments.
- Findings underscore the patient-experienced burden of moderate-to-severe cutaneous VMs and reinforce the value of patient-reported outcomes in clinical development.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones, Palvella’s plans to pursue Breakthrough Therapy Designation, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com
